Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Inoviq Ltd ( (AU:IIQ) ) has provided an announcement.
INOVIQ has appointed internationally recognised exosome and cell therapy specialist Dr Rebecca Lim as Chief Scientific Officer, effective 12 January 2026, to lead its research and development strategy across preclinical, clinical and regulatory programs in exosome capture tools, diagnostics and therapeutics. Lim’s more than 20 years’ experience in translational research, advanced therapy development and regulatory navigation in Australia and the US is expected to accelerate INOVIQ’s CAR-exosome therapeutic pipeline toward first-in-human studies and strengthen the company’s global leadership ambitions in exosome technologies, while founder Professor Greg Rice transitions to a part-time role as Founding Scientist and Advisor to ensure continuity of scientific oversight and diagnostics leadership during the next phase of growth.
The most recent analyst rating on (AU:IIQ) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Inoviq Ltd stock, see the AU:IIQ Stock Forecast page.
More about Inoviq Ltd
INOVIQ Ltd (ASX: IIQ) is an exosome technology company focused on next-generation cancer diagnostics and therapeutics. Its portfolio spans commercial-stage exosome isolation tools, clinical-stage diagnostic tests for ovarian and breast cancers, and a preclinical CAR-exosome therapeutic program targeting solid tumours, positioning the group at the forefront of exosome-based cancer detection and treatment.
Average Trading Volume: 167,521
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$47.16M
Find detailed analytics on IIQ stock on TipRanks’ Stock Analysis page.